Last reviewed · How we verify
Placebo to LET
At a glance
| Generic name | Placebo to LET |
|---|---|
| Sponsor | Merck Sharp & Dohme LLC |
| Modality | Small molecule |
| Phase | Phase 3 |
Approved indications
- Treatment of symptoms of osteoarthritis, rheumatoid arthritis, juvenile idiopathic arthritis, acute gouty arthritis, and ankylosing spondylitis
Common side effects
- Headache
- Nausea
- Diarrhea
- Dizziness
- Fatigue
Key clinical trials
- LET for Fibromyalgia (NA)
- Leukocyte-Poor Platelet-Rich Plasma Reduces Pain Symptoms in the Treatment of the Lateral Epicondylitis (NA)
- Extension of Letermovir (LET) From Day 100 to Day 200 Post-transplant for the Prevention of Cytomegalovirus (CMV) Infection in Hematopoietic Stem Cell Transplant (HSCT) Participants (MK-8228-040) (PHASE3)
- Nintedanib for the Treatment of SARS-Cov-2 Induced Pulmonary Fibrosis (PHASE3)
- Letermovir Versus Valganciclovir to Prevent Human Cytomegalovirus Disease in Kidney Transplant Recipients (MK-8228-002) (PHASE3)
- Reinforcement of Placebo Response in Knee Osteoarthritis: A Randomised Trial (NA)
- Functional Test for a Drink Powder Alone and Combined Use With a Cosmetic Apparatus (NA)
- Effects of a Probiotic on Oral Microbiota and Glycemic Control in Type 2 Diabetics; A Randomized Clinical Trial (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo to LET CI brief — competitive landscape report
- Placebo to LET updates RSS · CI watch RSS
- Merck Sharp & Dohme LLC portfolio CI